当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
Anthrasil, Anthrax Immune Globulin Intravenous (Human)
申请企业
Emergent BioSolutions Canada Inc.
药品名称
Anthrasil, Anthrax Immune Globulin Intravenous (Human)
承诺描述
Conduct a field study (protocol AX-003A) to evaluate the efficacy, pharmacokinetics, and safety of Anthrax Immune Globulin (Human) for the treatment of toxemia associated with inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs. The primary endpoint of this study will be all-cause mortality.